Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Overview

MONALEESA-2 Ribociclib Plus Letrozole vs Letrozole Plus Placebo

MONALEESA-2 Updated Results

MONALEESA-2: Grade 3/4 AEs

Additional Analyses of MONALEESA-2

MONALEESA-7

PALOMA-1: First-Line Therapy With Palbociclib

PALOMA-2: First-Line Therapy With Palbociclib

PALOMA-3: Palbociclib in Progressive Disease

MONARCH 1: Abemaciclib

MONARCH 2: Abemaciclib in Progressive Disease

MONARCH 3

MONARCH 3: Survival Data

MONARCH 3: Incidence of AEs

Differentiating Among the CDK 4/6 Inhibitors

Integrating the CDK 4/6 Inhibitors Into Practice

Management of ER+ Metastatic Breast Cancer in 2017

Treatment Indications for CDK 4/6 Inhibitors

Integrating the CDK 4/6 Inhibitors Into Practice: Unanswered Questions

Abbreviations

Abbreviations (cont)